Profits unlimited is an exciting and educative industry newsletter from Paul Mampilly, a retired hedge fund manager. The newsletter has over 60,000 subscribers. Mampilly continues to write the eight-page newsletter due to its popularity and public demand. He highlights a particular investment and explains why it’s good.
Profits Unlimited has been in circulation for only one year. Banyan Hill Publishing publishes the popular newsletter that has seen its subscribers rise steadily throughout the year. Mampilly picks, at most, two stocks from a recommended portfolio and makes weekly updates. So far, 85% of the stocks he picks remain profitable. One even increased in value by more than 150 percent.
Reason Behind Profits Unlimited’s Success
Mampilly’s advice is a proven recipe for success, a factor that has made his newsletter so successful. He won the esteemed 2009 investment competition organized by Templeton Foundation after an $88 million yield from a $50 million investment. Moreover, the 75 percent gain came during the 2008/2009 recession that hit America hard.
His impressive investment captured many people’s attention from industry experts to aspiring investors. His newsletter is also successful because it contains detailed and useful information on investing. Paul Mampilly writes in an easy-to-understand language, which makes his passion rub off on readers.
One thing that stands out about Mampilly’s newsletter is the fact that he chooses to empower his readers instead of doing everything for them. He teaches them how to trade stocks, open and manage their brokerage accounts, update their portfolios, as well as track relevant information. Newsletter subscribers can trade using their computers, tablets, or phones. They also receive monthly briefings and updates on new stocks and are served by customer service agents.
Critical Example of How Profits Unlimited Is Beneficial
True to his nature, Mampilly recently posted excellent examples of how subscribers can benefit from his investment strategies. Apart from becoming members of his inner circle, Mampilly can advise you on various pitfalls to avoid. Upon discovering that Sarepta Therapeutics was producing a pharmaceutical therapy for muscular dystrophy, Mampilly deemed it necessary to invest on the high wave. A few months later, the investment proved to be lucrative and earned him immense profits.
Paul Mampilly is an Indian native who migrated to the US when he was young. He is a successful financial expert and investor with two decades of experience in Wall Street. He started his career at Deutsche Bank in 1991. He has also worked at the Royal Bank of Scotland and Kinetics International Fund. He retired aged 42 but remains involved in Profits Unlimited.
Like Paul Mampilly on Facebook